Sommaire

• • ·Editorial board

    Article :101341

    
• • ·Sommaire

    Article :101342

    

• Reviews

  • ·Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design

    Article :101281

    Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad, Arun J. Sanyal

    Résumé Résumé Plan Plan  
  • ·Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers

    Article :101315

    André J Scheen, Pierre Delanaye

    Résumé Résumé Plan Plan

• Original articles

  • ·Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach

    Article :101289

    Evelyne Liuu, Pierre-Jean Saulnier, Elise Gand, Gautier Defossez, Amélie Jamet, Stéphanie Ragot, Marc Paccalin, Samy Hadjadj, SURDIAGENE study group

    Résumé Résumé Plan Plan   
  • ·MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance.

    Article :101292

    Cristina Bianchi, Francesco Raggi, Chiara Rossi, Simona Frontoni, Riccardo C. Bonadonna, Stefano Del Prato, Anna Solini

    Résumé Résumé Plan Plan   
  • ·Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs

    Article :101305

    Wajd Alkabbani, John-Michael Gamble, Dean T Eurich, Jasjeet K Minhas-Sandhu, Baiju R Shah, Mhd. Wasem Alsabbagh, Arsène Zongo

    Résumé Résumé Plan Plan   
  • ·Prevention of exercise-induced hypoglycemia in 12 patients with type 1 diabetes running the Paris Marathon using continuous glucose monitoring: A prospective, single-center observational study

    Article :101321

    Philippe Thuillier, Nikhil Domun, Emmanuel Sonnet, Florent Le Ven, Caroline Roudaut, Anne Kergus, Véronique Kerlan, Nathalie Roudaut

    Résumé Résumé Plan Plan   
  • ·Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

    Article :101325

    Andre J. Scheen

    Résumé Résumé Plan Plan   

• Short report

  • ·Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins

    Article :101284

    Bruno Vergès, Jonathan Hassid, Alexia Rouland, Benjamin Bouillet, Isabelle Simoneau, Jean-Michel Petit, Laurence Duvillard

    Résumé Résumé Plan Plan

• Letters to the editor

  • ·Comment on “Elevated triglyceride–glucose index predicts risk of incident ischemic stroke: The Rural Chinese cohort study”

    Article :101314

    Roomi Raja, Satesh Kumar

     
  • ·Fulminant type 1 diabetes after COVID-19 vaccination

    Article :101324

    Xiaohan Tang, Binbin He, Zhenqi Liu, Zhiguang Zhou, Xia Li

     

• Research letters

  • ·Skin autofluorescence predicts mortality in type 1 diabetes

    Article :101273

    Alice Larroumet, Ninon Foussard, Camille Majchrzak, Marie Monlun, Laurence Blanco, Kamel Mohammedi, Vincent Rigalleau

     
  • ·The progressive uncoupling of maternal insulin clearance and insulin sensitivity across gestation

    Article :101291

    Mireille N.M. van Poppel, Ravi Retnakaran

    Plan Plan  
  • ·Monitoring gestational diabetes mellitus patients with the telemedicine application MyDiabby decreases the rate of foetal macrosomia

    Article :101301

    Tiphaine Meykiechel, Céline de Carne, Isabelle Gueguen, Camille Vatier, Guillaume Girard, Jean-Claude Buzzi, Sophie Christin-Maitre, Nathalie Bourcigaux

    
  • ·Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial

    Article :101304

    Ikaro Breder, Vaneza Lira W. Wolf, Alexandre A.S. Soares, Luiz Sergio F. de Carvalho, Sheila T. Kimura-Medorima, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Jessica S. Cunha, Isabella Bonilha, Otavio R. Coelho-Filho, Thiago Quinaglia, Wilson Nadruz, Gil Guerra-Junior, Elza Muscelli, Andrei C. Sposito, ADDENDA-BHS2 Trial Investigators

    Plan Plan
  • ·Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis

    Article :101317

    Conner Howard, Nicholas B. Sajjadi, Samuel Shepard, Jourdan Waddell, Stacy M. Chronister, Matt Vassar, Micah Hartwell

    Plan Plan
  • ·Variable incidence of ketoacidosis in youth with type 1 diabetes onset during COVID-19 pandemic peaks in France

    Article :101322

    Juliette Delpeut, Elisa Giani, Dalila Louet, Marc de Kerdanet, Carine Choleau, Jacques Beltrand, the AJD Study Group (see appendix on line)

    Plan Plan